Impact of Brokerage Rating on Keryx Biopharmaceuticals, Inc.(KERX)

Many Keryx Biopharmaceuticals, Inc.(KERX) Stock Research Financial Advisors from Investment Banking firms have advised their client and investors on the stock. Keryx Biopharmaceuticals was Upgraded by Citigroup to Neutral on Jan 11, 2017.

Company has reported several Insider transactions to the SEC, on Feb 13, 2017, Greg Madison (President and CEO) sold 1,611 shares at 5.47 per share price.On Jan 31, 2017, Scott A Holmes (Chief Financial Officer) sold 8,447 shares at 4.65 per share price.On Jan 31, 2017, John F. Neylan (Chief Medical Officer) sold 6,984 shares at 4.65 per share price.

Keryx Biopharmaceuticals Last issued its quarterly earnings results on Nov 9, 2016. The company reported $-0.39 EPS for the quarter, missing the analyst consensus estimate by $ -0.19. Analyst had a consensus of $-0.20. The company had revenue of $6.30 million for the quarter, compared to analysts expectations of $5.53 million. The companys revenue was up 50.0% compared to the same quarter last year. During the same quarter in the previous year, the company posted $-0.29 EPS.

Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX) has received a short term rating of hold from experts at Zacks with a rank of 3. The stock has been rated an average of 2.38 by 8 Brokerage Firm. 2 Wall Street Firms have rated the stock as a strong buys. 1 stock experts have also suggested a buy rating. 5 Brokerage Firms have advised hold.

Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX) stock has received a short term price target of $ 6.43 from 7 Analyst. The share price can be expected to fluctuate from the mean short term target, can be seen from the standard deviation reading of $1.62. The higher estimate of target price is $9 , while the lower price target estimate is $4

Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX) witnessed a decline in the market cap on Tuesday as its shares dropped 0.18% or 0.01 points. After the session commenced at $5.5, the stock reached the higher end at $5.62 while it hit a low of $5.38. With the volume soaring to 865,917 shares, the last trade was called at $5.53. The company has a 52-week high of $7.8. The company has a market cap of $586 million and there are 105,960,364 shares in outstanding. The 52-week low of the share price is $3.17.

Keryx Biophamaceutical, Inc. uses data discovered through the mapping of the human genome to generate drug candidates that target the regulation of protein kinases. Protein kinases play a key role in the way cells communicate.

Keryx

Share this post

Leave a Reply